Cyclofenil

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Cyclofenil

Articles

Most recent articles on Cyclofenil

Most cited articles on Cyclofenil

Review articles on Cyclofenil

Articles on Cyclofenil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cyclofenil

Images of Cyclofenil

Photos of Cyclofenil

Podcasts & MP3s on Cyclofenil

Videos on Cyclofenil

Evidence Based Medicine

Cochrane Collaboration on Cyclofenil

Bandolier on Cyclofenil

TRIP on Cyclofenil

Clinical Trials

Ongoing Trials on Cyclofenil at Clinical Trials.gov

Trial results on Cyclofenil

Clinical Trials on Cyclofenil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cyclofenil

NICE Guidance on Cyclofenil

NHS PRODIGY Guidance

FDA on Cyclofenil

CDC on Cyclofenil

Books

Books on Cyclofenil

News

Cyclofenil in the news

Be alerted to news on Cyclofenil

News trends on Cyclofenil

Commentary

Blogs on Cyclofenil

Definitions

Definitions of Cyclofenil

Patient Resources / Community

Patient resources on Cyclofenil

Discussion groups on Cyclofenil

Patient Handouts on Cyclofenil

Directions to Hospitals Treating Cyclofenil

Risk calculators and risk factors for Cyclofenil

Healthcare Provider Resources

Symptoms of Cyclofenil

Causes & Risk Factors for Cyclofenil

Diagnostic studies for Cyclofenil

Treatment of Cyclofenil

Continuing Medical Education (CME)

CME Programs on Cyclofenil

International

Cyclofenil en Espanol

Cyclofenil en Francais

Business

Cyclofenil in the Marketplace

Patents on Cyclofenil

Experimental / Informatics

List of terms related to Cyclofenil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cyclofenil (INN, trade names Ondogyne, Sexovid, and others) is a selective estrogen receptor modulator. It was investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective.Later study of its efficacy in treating Raynaud's phenomenon in people with scleroderma also found no statistically significant benefit.

References


Linked-in.jpg